Drug Evaluations: Drug Evaluation Anti-infectives: Famciclovir - origins, progress and prospects

References to Primarv Literature

• DARBY G: In search of the perfect antiviraL Antiviral Chem. Chemother. (1995) 6\(Suppl. 1):54–63.
   Google Scholar
• TILSONFIFI, ENGLE CR, ANDREWS EB: Safety of acyclovir: a summary of the first 10 years' experience. J. Med . ViroL (1993) SuppL 1:67–73.
   Google Scholar
• WELLER S, BLUM MR, DOUCETTE M et al.: Pharmacoki-netics of the aciclovir pro-drug valacklovir after esca-lating single and multiple dose administration to normal volunteers. Clin. Pharrnacol. Tber. (1993) 54:595–605.
   PubMed Web of Science ®Google Scholar
• DREW WL: Cytomegalovirus infection in patients with AIDS. Glin. Infect. Eris. (1993) 14:608–615.
   Web of Science ®Google Scholar
• ASHIDA N, LJICI-LI K, WATANABE Y, MACHIDA H: Metabo-lism of 5'-ether prodrugs of 1-beta-D-arabinoruranosyl-E-5-(2-bromovinyOuracil in rats. Biochem. Pharrnacol. (1993) 46:2201–2207.
   PubMedGoogle Scholar
• MEETING REPORT: 8th International Conference onantiviral research. Int. Antiviral News (1995) 3:101.
   Google Scholar
• T1PPIE MA, MARTIN JC, SMEE DF, MATTHEWS TR, VERHEY-DEN JPH: Antiherpes simplex virus activity of 9-(-4-hy-droxy-3-(hydroxymethyl)-1-buty0guanine. Nucleosides Nucleotides (1984) 3:525–535.
   Google Scholar
• HARNDEN MR, JARVEST An improved synthesis ofthe antiviral acyclonucleoside 9-(4-hydroxy-3-hy-droxymethbut-1-y1) guanine. Tetrahedron Lett. (1985) 6:4265–4268.
   Google Scholar
• BOYD MR, BACON TH, SUTTON D, COLE M: Antiherpes-virus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yOguanine (BRL 39123) in cell culture. Antimicrob. Agents Chemother. (1987) 31:1238–1242.
   Google Scholar
• DATEMA R, ERICSON A-C, FIELD HJ, LARSSON A, STEN-BERG K: Critical determinants of antiherpes efficacy of buciclovir and related acyclic guanosine analogs. An-tiviral Res. (1987) 7:303–316.
   PubMed Web of Science ®Google Scholar
• BOYD MR, BACON TH, SUTTON D: Antiherpesvirus ac-tivity of 9-(4-hydrox-y-3-hydroxymethylbut-1-yOgua-nine (BRL 39123) in animals. Antimicrob. Agents Chemother. (1988) 32:358–363.
   PubMed Web of Science ®Google Scholar
• CROOKS RJ, MURRAY A: Valaciclovir - a review of apromising new antiherpes agent. Antiviral Chem. Chemother. (1994) 5\(Suppl. 1):31–37.
   Google Scholar
• VERE HODGE RA, SUTTON D, BOYD MR, HARNDEN MR,JARVEST RE: Selection of an oral prodrug (BRL 42810: famcidovir) for the antiherpesvirus agent BRL 39123 19-(4-hydroxy-3-hydroxymethylbut-1-y1) guanine; pen-Antimicrob. Agents Chemother. (1989) 33:1765–1773.
   PubMed Web of Science ®Google Scholar
• WINTON CF, FOWLES SE, PIERCE DM, VERE HODGE RA:Gradient high-performance liquid chromatographic method for the analysis of the pro-drug famciclovir and Its metabolites, including the active anti-viral agent pendclovir, in plasma and urine. Analytical Proceedings (1990) 27:181–182.
   Google Scholar
• WINTON CF, FOWLES SE, VERE-HODGE RA, PIERCE DM:Assay of famciclovir and its metabolites, including the anti-herpes agent penciclovir, in plasma and urine of rat, dog and man. In: Analysis of Drugs and Metabolites. Reid E, Wilson ID (Eds.), (1990)163–171.
   Google Scholar
• VERE HODGE RA: Famciclovir and penciclovir. The mode of action of famciclovir including its conversionto pencidovir. Antiviral Chem. Chemother. (1993) 4:67–84.
   Google Scholar
• PUT MA, BENET LZ: Phartnacokinetks of famcidovir in man. Antiviral Chem. Chemother. (1993) 4\(Suppl. 1):47–55.
   Google Scholar
• VERE HODGE RA, PERKINS RM: Mode of action of 944-hydroxy-3-hydroxymethlybut-1-y1) guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob. Agents Chemother. (1989) 33:223–229.
   PubMed Web of Science ®Google Scholar
• EARNSHAW DL, BACON 1E, DARLISON SJ et al.: Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob. Agents Chemother. (1992) 36:2747–2757.
   Google Scholar
• VERE HODGE RA, CHENG Y-C: The mode of action ofpenciclovir. Antiviral Chem. Chemother. (1993) 4\(Suppl.1):13–24.
   Google Scholar
• BOYD MR, SAFRIN S, KERN ER: Penciclovir: a review ofIts spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chem. Chemother. (1993) 4\(Suppl. 1):3–11.
   Google Scholar
• TSIQUAYE KN, SLOMKA MJ, MAUNG M: Oral famciciovir against duck hepatitis B virus replication in hepatic and non-hepatic tissues of ducklings infected in ovo. J. Med. Viral. (1994) 42:306–310.
   PubMed Web of Science ®Google Scholar
• LOCARNINI SA, SHAW T, AMOR P, BOYD MR: Antiviral activity of pencidovir, a novel antiherpesvirus com-pound, against duck hepatitis B virus in vitro. Antiviral Res. (1994) 23\(Suppl. 1):82.
   Google Scholar
• KORBER BE, BOYD MR: Pencidovir is a selective inhibi-tor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob. Agents Chemother. (1996) 40:1282–1284.
   PubMed Web of Science ®Google Scholar
• ZOULIM F, SEEGER C: Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of polymerase. Viral. (1994) 68:6–13.
   PubMed Web of Science ®Google Scholar
• ZOULIM et al.: Inhibitory effect of penciclovir on the priming of hepadnavirus reverse transcription. 35th ICAAC. San Francisco (1995). Abstract H13.
   Google Scholar
• ERTL P, SNOWDEN W, LOWE D et al.: A comparative study of the in vitro and in vivo antiviral activities of acyckwir and penciclovir. Antiviral Chem. Chemotber. (1995) 6:89–97.
   Google Scholar
• LOWE DM, ALDERTON WK, ELLIS MR et al.: Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyDbutyl]guattine against herpesviruses. Antimicrob. Agents Chemother. (1995) 39:1802–1808.
   Google Scholar
• BACON TH, STANDRING-COX R, HOWARD BA el al.: Comparative activity of penciclovir and acyclovir against herpes simplex virus type 2 in cell culture. Antiviral Res. (1994) 23\(Suppl. 1):68.
   Google Scholar
• BACON TH, SCHINAZI RF: An overview of the further evaluation of pendclovir against herpes simplex virus and varicella-zoster virus in cell culture highlighting contrasts with acyclovir. Antiviral Chem. Chemother. (1993) 4\(Suppl. 1):25–36.
   Google Scholar
• BACON TH, BOYD MR: Activity of penciclovir against Epstein-Barr virus. Antimicrob. Agents Chemother. (1995) 39:1599–1602.
   PubMed Web of Science ®Google Scholar
• BACON, TH, HOWARD BA: Further characterization ofthe potent and prolonged inhibition of herpes simplex virus replication in human cell lines by penciclovir. Antiviral Chem. Chemother. (1996) 7:128–137.
   Web of Science ®Google Scholar
• STANDRING-COX R, BACON TH, HOWARD BA, GILBARTJ, BOYD MR: Prolonged activity of penciclovir in cell culture against varicella-zoster virus. Antiviral Res. (1994) 23\(Suppl. 1):114.
   Google Scholar
• BACON TH, GILBART J, HOWARD BA, STANDRING-COXR: Inhibition of varkella-zoster virus by pencidovir in cell culture and mechanism of action. Antiviral Chem. Chemother. (1996) 7:71–78.
   Web of Science ®Google Scholar
• ILSLEY DD, LEE S-H, MILLER WH, KUCHTA RD: Acyclicguanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action. Biochemistry (1995) 34:2504–2510.
   PubMed Web of Science ®Google Scholar
• EARNSHAW DL, VERE HODGE RA: Effective inhibition ofherpes virus DNA synthesis by (S)-penciclovir-triphos-phate. 32nd ICAAC. Anaheim (October 11–14, 1992). Poster 1707.
   Google Scholar
• BALZARINI J, BOHMAN C, WALKER RT, DE CLERCQ E:Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine Mame gene-transfected tumor cells. Mol. Pharmacol. (1994) 45:1253–1258.
   PubMed Web of Science ®Google Scholar
• SALTZMAN R, BOON R: The safety of famciclovir inpatients with herpes zoster. Carr. Ther Res. (1995) 56:219–225.
   Web of Science ®Google Scholar
• SALTZMAN R, JUREWICZ R, BOON R: Safety of famciclovirin patients with herpes zoster and genital herpes. Antimicrob. Agents Chemother. (1994) 38:2454–2457,
   PubMed Web of Science ®Google Scholar
• DANIELS S, SCHENTAG JJ: Drug interaction studies andsafety of famcklovir in healthy volunteers: a review. Antiviral Chem. Chemother. (1993) 4\(Suppl. 1):57–64.
   Google Scholar
• PUE MA, PRATT SK, FAIRLESS AJ et al.: Linear pharmacok-inetics of penciclovir following administration of single oral doses of famcklovir 125, 250, 500 and 750 mg to healthy volunteers. J. Antimicrob. Chemother. (1994) 33:119–127.
   PubMed Web of Science ®Google Scholar
• FOWLES SE, PIERCE DM, PRINCE WT, THOW JC: Effect offood on the bioavailability and pharmacokinetics of penciclovir, a novel antiherpes agent, following oral administration of the pro-drug, famciclovir. Br. J. Clin. Pharmacol. (1990) 29:620–621.
   Google Scholar
• FOWLES SE, FAIRLESS AL PIERCE DM, PRINCE WT: A further study of the effect of food on the bioavallability and pharmacokinetics of penddovir after oral admini-stration of famcidovir. Br. J. Clin. Pharmacol. (1991) 32:657.
   Google Scholar
• PRATT SK, PUE MA, FAIRLESS AJ et al.: Lack of an effectof gender on the pharmacokinetics of pencidovir fol-lowing single oral doses of famcklovir. Br. J. Clin. Pharmacol. (1994) 37:493.
   Google Scholar
• BOIKE SC, PUE MA, FREED MI eta!,: Pharmacokinetks offamcidovir in subjects with varying degrees of renal Impairment Clin. Pharrnacol. Ther. (1994) 55:418–426.
   PubMed Web of Science ®Google Scholar
• VERE HODGE A: Chirality presents a challenge: famci- clovir - a case study. Int. Antiviral News (1995) 3:71–73.
   Google Scholar
• SCHINAZI RF et al.: Differential inhibition of viral po-lymerases by enantiomers of penciclovir triphosphate. 35th ICAAC. San Francisco (1995). Abstract H104.
   Google Scholar
• FURMAN PA, WILSON JE, REARDON JE, PAINTER GE: Theeffect of absolute configuration on the anti-111V and anti HBV activities of nucleoside analogues. Antiviral Chem. Chemother. (1995) 6:345–355.
   Web of Science ®Google Scholar
• FILER CW, RAMP JV, ALLEN GD et al.: Metabolic andpharmacokinetic studies following oral administration of famcklovir to the rat and dog. Xenobiotica (1995) 23:477–490.
   Google Scholar
• HARNDEN MR, JARVEST RL, BOYD MR, SUTTON D, VERE HODGE RA: Prodrugs of the selective antiherpesvirus agent 944-hydroxy-3-(hydroxymethyl)but- 1-yl)gua-nine (BRL 39123) with improved gastrointestinal prop-erties. J Med. Chem. (1989) 32:1738–1743.
   PubMed Web of Science ®Google Scholar
• FIELD HJ, TEWARI D, SUTTON D, THACKRAY AM: Com-parison of efficacies of famcklovir and valacklovir against herpes simplex virus type 1 in a murine immu-nosuppression modeL Antimicrob. Agents Chemother. (1995) 39:1114–1119.
   PubMed Web of Science ®Google Scholar
• FIELD HJ, AWAN AR FUENTE DE LA R: The acyclic nucleo-side analogue penciclovir is a potent inhibitor of equine herpesvirus type 1 (EHV-1) in tissue culture and in a murine model- Antiviral Res. (1992) 18:77–89.
   Google Scholar
• ASHTON RJ, ABBOTT KB, SMITH GM, surroN D: Antivi-ral activity of famcidovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16. I Antimicrob. Chemother. (1994) 34:287–290.
   PubMed Web of Science ®Google Scholar
• GOLDTHORPE SE, BOYD MR, FIELD HJ: Effects of pend-clovir and famdclovir in a murine model of encephali-tis induced by intranasal inoculation of herpes simplex virus type 1. Antiviral Chem. Chemother. (1992) 3:37–47.
   Google Scholar
• SUTTON D, KERN ER: Activity of famdclovir and penci-dovir in HSV-infected animals: a review. Antiviral Chem. Chernother (1993) 4\(Suppl. 1):37–46.
   Google Scholar
• FIELD HJ, THACKRAY AM: The effects of delayed-onset chemotherapy using famcklovir or valaciclovir in a murine immunosuppression model for HSV-1. Antiviral Chem. Chemother. (1995) 6:210–216.
   Web of Science ®Google Scholar
• FIELD HJ, THACKRAY AM: Valacklovir and famcklovir-differences between two similar guanosine analogueprodrugs emerge from laboratory models. Int. Antiviral News (1996) 4:23–27.
   Google Scholar
• THACKRAY AM, FIELD HJ: Differential effects of famci-clovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency. J. Infect. Dis. (1996) 173:291–299.
   PubMed Web of Science ®Google Scholar
• THACKRAY AM, FIELD HJ: Comparison of effects of famcklovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model. Antimicrob. Agents Chernother. (1996) 40. In press.
   Google Scholar
• TSIQUAYE KN, SLOMKA MJ, MAUNG M: Oral famckloviragainst duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. J. Med. Virol. (1994) 42:306–310.
   PubMed Web of Science ®Google Scholar
• LIN E, LUSCOMBE C, WANG YY, SHAW T, LOCARNINI S:The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob. Agents Chemother. (1996). In press.
   Google Scholar
• TSIQUAYE KN, SUTTON D, MAUNG M. BOYD MR: Antiviral activities and pharmacokinetics of penciclovir and famciclovir in Pekin ducks chronically infected with duck hepatitis B virus. Antiviral Chem. Chemother. (1996) 7:153–159.
   Google Scholar
• LITTLER E: Safety and efficacy issues of herpesvirusdrugs. Antiviral Chem. Chemother. (1994) 5\(Suppl. 1):11–16.
   Google Scholar
• CHIOU HC, KUMURA K, HU A, KERNS KM, COEN DM: Penciclovir-resistance mutations in the herpes simplex virus DNA polymerase gene. Antiviral Chem. Chemother. (1995) 6:281–288.
   Web of Science ®Google Scholar
• CORROCHENO LM, MADUENO F, FIELD HJ, FUENTE DELA R: Sequence analysis of thymidine kinase-defective mutants of equine herpesvirus-1 (EHV-1). Gene (1993) 126:257.
   PubMed Web of Science ®Google Scholar
• MERTZ GJ, LOVELESS MO, LEVIN MJ et al. AND THE COLLABORATIVE FAMCICLOVIR GENITAL HERPES RE-SEARCH GROUP: Oral famcidovir for suppression of recurrent genital herpes simplex virus infection in women: a multicenter, double-blind, placebo-control-led triaL Arch. Intern. Med. (1996). In press.
   Google Scholar
• SACKS SL, AOKI FY, DIAZ-MITOMA F et al.: Patient-initi-ated, twice daily oral famcidovir for early recurrent genital herpes - a randomized, double-blind multicen-ter triaL JAMA (1996) 276(1):44–49.
   Google Scholar
• DEGREEF H, FAMCICLOVIR HERPES ZOSTER CLINICAL STUDY GROUP: Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study dem-onstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in itumunocompetent pa-tients. Int. J. Antimicrob. Agents (1994) 4:241–246.
   PubMed Web of Science ®Google Scholar
• TYRING S, BARBARASH RA, NAHLIK JE et al.: Famciclovir for the treatment of acute herpes zoster: effects of acute disease and postherpetic neuralgia. A randomized, dou-ble-blind, placebo-controlled triaL Ann. Intern. Med. (1995) 123:89–96.
   Google Scholar